Rheumatoid Arthritis
  • Featured content
    In this resource, Jasvinder Singh, MD, MPH, reviews optimal management of patients with RA in accordance with ACR and EULAR recommendations, including:
      • Drug indications in early vs established disease
      • Monitoring for adverse events
      • Treatment strategies in high-risk populations
  • Featured content
    Clinical trial data to date have shown tofacitinib and baricitinib to be largely similar in efficacy and safety. But are there meaningful differences that might help clinicians choose between them? Here’s my take.
    Date Posted: 9/9/2016
  • Featured content
    In this downloadable slideset, Gregg J. Silverman, MD, and William F. C. Rigby, MD, discuss the indications, mechanisms of action, and recent pivotal trial data regarding Janus kinase inhibitors in the management of rheumatoid arthritis.
    Date Posted: 8/1/2016
  • Featured content
    Consideration of tapering RA therapy is a careful balance between sustained remission and drug tolerability. Here is my take on determining when it is appropriate and which agents to taper.
    Date Posted: 7/14/2016
  • Featured content
    The updated ACR guideline encourages us to reconsider the use of glucocorticoids for patients with RA. Here’s my take.
    Date Posted: 6/9/2016
  • 1
  • 2
  • 3
  • 4
  • 5

Latest Content

10 of 50 Shown
10 of 50 Shown
Show 10 More
Loading...